Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
ZEVRA THERAPEUTICS, INC. (KMPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Investor presentation
Docs: " ",
" "
03/07/2023 8-K Investor presentation, Quarterly results
Docs: " ",
" "
11/09/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/30/2022 8-K Investor presentation, Quarterly results
Docs: " ",
" "
11/10/2021 8-K Investor presentation, Quarterly results
Docs: " ",
" ",
" "
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "KemPharm Reports Second Quarter 2021 Financial Results Corporate and Regulatory Highlights",
"Presentation titled "Second Quarter 2021 Results""
05/13/2021 8-K Quarterly results
04/08/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
11/23/2020 8-K Investor presentation
Docs: "KemPharm Provides Update on Development Pipeline",
"Presentation titled "Management Presentation" dated November 2020"
10/29/2020 8-K Investor presentation, Quarterly results
Docs: "KemPharm Reports Third Quarter 2020 Financial Results",
"Presentation titled "Q3 2020 Results""
08/12/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
12/18/2019 8-K Investor presentation
Docs: "Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock",
"Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock",
"December 2019 Exchange Agreement and Amendment to Facility Agreement, Senior Secured Convertible Notes and Warrants, by and among KemPharm, Inc., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. and Delaware Street Capital Master Fund, L.P",
"Amendment to September 2019 Exchange Agreement and Amendment to Facility Agreement, by and among KemPharm, Inc., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P",
"Form of Senior Secured Convertible Note, with a schedule of noteholders",
"Amended and Restated Senior Secured Convertible Note issued to Deerfield Private Design Fund III, L.P.",
"Amended and Restated Guaranty and Security Agreement, by and among KemPharm, Inc., each other Grantor party thereto, each Guarantor party thereto and Deerfield Private Design Fund III, L.P., as collateral agent",
"KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital",
"Management Presentation"
11/14/2019 8-K Quarterly results
09/04/2019 8-K Investor presentation
Docs: "KemPharm, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock",
"KemPharm, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock",
"September 2019 Exchange Agreement and Amendment to Facility Agreement, by and among KemPharm, Inc., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P",
"Collaboration and License Agreement, by and between KemPharm, Inc. and Boston Pharmaceuticals Holdings SA",
"KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital",
"Management Presentation"
04/11/2019 8-K Investor presentation
Docs: "KemPharm Completes KP415 Pre-NDA Meeting with FDA",
"Presentation titled "KP415 Pre-NDA Meeting Update Call""
03/13/2019 8-K Investor presentation
Docs: "KemPharm Provides Update on APADAZ Formulary Adoption",
"Presentation titled "APADAZ® Commercial Update Call""
02/28/2019 8-K Investor presentation
Docs: "KemPharm Reports Q4 and FY 2018 Results",
"Presentation titled "Quarterly Update Call - Q4 and FY 2018""
12/06/2018 8-K Investor presentation
Docs: "Presentation titled "Management Presentation" dated December 2018"
11/08/2018 8-K Investor presentation, Quarterly results
Docs: "KemPharm, Inc. Reports Third Quarter 2018 Results",
"Presentation titled "Q3 2018 Results""
10/30/2018 8-K Investor presentation
Docs: "Presentation titled "Management Presentation""
09/17/2018 8-K Investor presentation
Docs: "Presentation titled "Janney Healthcare Conference""
08/09/2018 8-K Investor presentation, Quarterly results
Docs: "KemPharm, Inc. Reports Second Quarter 2018 Results",
"Presentation titled "Q2 2018 Results""
08/09/2018 8-K Investor presentation
Docs: "Presentation titled "Canaccord Genuity 38th Annual Growth Conference""
07/09/2018 8-K Investor presentation
Docs: "KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD",
"Presentation titled "KP415.E01 Efficacy Trial Results""
05/10/2018 8-K Investor presentation
Docs: "KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results",
"Presentation titled "Q1 2018 Results""
03/29/2018 8-K Investor presentation
Docs: "KemPharm Reports Fourth Quarter and Year End 2017 Results",
"Presentation titled "Q4 and FY 2017 Results""
02/23/2018 8-K Investor presentation
Docs: "KemPharm Announces FDA Approval of Apadaz™ for the Short-Term Management of Acute Pain",
"Presentation titled "Apadaz™ FDA Approval""
11/09/2017 8-K Investor presentation, Quarterly results
Docs: "KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update",
"Presentation titled "Third Quarter 2017 Results""
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy